SPC
BIIB icon

Spirepoint Private Client’s Biogen BIIB Stock Holding History

Spirepoint Private Client’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,338
Closed -$205K – 217
2024
Q4 		$205K Sell
1,338
-11
-0.8% -$1.85K 0.03% 214
2024
Q3 		$261K Hold
1,349
– – 0.03% 181
2024
Q2 		$313K Hold
1,349
– – 0.04% 170
2024
Q1 		$291K Buy
+1,349
New +$316K 0.04% 170

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Spirepoint Private Client's BIIB Position: Q1 2025 in Review

Spirepoint Private Client sold out of Biogen (BIIB) in Q1 2025, closing a stake of 1,338 shares — an estimated $205K sold.

Spirepoint Private Client first reported a position in BIIB in Q1 2024 and held it in 4 quarters. The position peaked at $313K in Q2 2024. 883 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.

  • Spirepoint Private Client reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
  • Spirepoint Private Client sold 1,338 Biogen shares in Q1 2025, an estimated $205K.
  • Spirepoint Private Client first reported a position in Biogen in Q1 2024 and held it in 4 quarters.
  • Spirepoint Private Client's Biogen position peaked at $313K in Q2 2024.
  • 883 funds tracked by Wall St. Rank held Biogen as of Q1 2025.

Based on Spirepoint Private Client's 13F filing for Q1 2025, filed 23 Apr 2025.